Product Description: TG4-155 is a potent, brain-permeant and selective EP2 receptor antagonist with a Ki of 9.9 nM[1][2]. TG4-155 shows low nanomolar antagonist activity against only EP2 and DP1[1]. TG4-155 has an EP2 Schild KB of 2.4 nM and displays 550-4750-fold selectivity for EP2 over EP1, EP3, EP4 and IP, but only 14-fold selectivity against the DP1 receptor[2].
Applications: COVID-19-immunoregulation
Formula: C23H26N2O4
References: [1]Jiang J, et al. Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation. J Pharmacol Exp Ther. 2013 Feb;344(2):360-7./[2]Ganesh T. Prostanoid receptor EP2 as a therapeutic target. J Med Chem. 2014 Jun 12;57(11):4454-65./[3]Jiang J, et al. Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2. Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3149-54.
CAS Number: 1164462-05-8
Molecular Weight: 394.46
Compound Purity: 99.91
Research Area: Inflammation/Immunology; Neurological Disease; Endocrinology; Cancer
Solubility: DMSO : 125 mg/mL (ultrasonic)
Target: Prostaglandin Receptor
Deutsch
English
